Raptor Pharmaceutical Granted Additional Orphan Drug Designation

Date Posted:
Jan 26, 2016

Novato-based Raptor Pharmaceutical Inc. has announced that it has been granted additional orphan drug designation for PROCYSBI, to treat nephropathic cystinosis in children aged 2 to 6 years old, and has received four new patents related to PROCYSBI within the last three months. The seven-year term of orphan exclusivity for the treatment’s newest pediatric indication will run through August 2022. The FDA’s Orphan Drug Designation program grants orphan status to drugs intended for the treatment of rare disorders affecting fewer than 200,000 people in the U.S.

For more information, visit the Raptor Pharmaceutical website.